These findings suggest that combining Osimertinib with MEK inhibition can potentially delay cell resistance and enhance the induction of apoptosis in future treatment of EGFR-mutant NSCLC [62]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.